文献速递腹部CTMR

LI-RADS治疗反应算法检测肝癌局部治疗后不完全坏死的系统评价与个体患者数据Meta分析

LI-RADS treatment response algorithm for detecting incomplete necrosis in hepatocellular carcinoma after locoregional treatment: a systematic review and meta-analysis using individual patient data.
PubMed 文献 · Abdom Radiol (NY) · 2021-05-23

该系统评价与个体患者数据Meta分析纳入6项研究共393例患者534个病灶,评估LI-RADS治疗反应算法在CT或MRI上以病理为参考标准检测肝细胞癌局部治疗后不完全坏死的诊断效能。汇总敏感度为0.56(95%CI 0.43-0.69),特异度为0.91(95%CI 0.84-0.96);动脉期高强化是最主要标准,消融术后敏感度低于栓塞术后。

要点

  • LI-RADS TR算法检测不完全坏死敏感度中等(0.56)、特异度高(0.91)。
  • 动脉期高强化是主要贡献标准,敏感度0.67;廓清贡献小但有意义。
  • 消融术后敏感度低于栓塞术后(0.42 vs 0.65,p=0.033)。

核心结论

  • LI-RADS TR算法检测局部治疗后不完全坏死具有中等敏感度和高特异度。
  • 动脉期高强化是主要诊断标准,廓清贡献小而有一定意义,强化与治疗前相似贡献可忽略。
  • 局部治疗类型可能影响算法效能,消融术后敏感度低于栓塞术后。

研究设计与样本

  • 纳入6项研究,共393例患者、534个病灶,以病理为参考标准。
  • 评估CT或MRI上LI-RADS TR算法检测不完全坏死的诊断准确性,采用随机效应模型汇总敏感度和特异度。

诊断标准与关键数值

  • 汇总敏感度0.56(95%CI 0.43-0.69),汇总特异度0.91(95%CI 0.84-0.96)。
  • 动脉期高强化敏感度0.67(95%CI 0.51-0.81),廓清0.43(95%CI 0.26-0.62),强化与治疗前相似0.24(95%CI 0.15-0.36)。
  • 不完全坏死病灶中,仅表现为廓清而无动脉期高强化者占2%(95%CI 0.00-0.05),仅表现为强化与治疗前相似而无动脉期高强化和廓清者占0%(95%CI 0.00-0.02)。
  • 消融术后敏感度0.42(95%CI 0.28-0.57),栓塞术后0.65(95%CI 0.53-0.77),差异p=0.033。
  • MRI与CT敏感度和特异度比较p值分别为0.783和0.290。

临床应用与阅片要点

  • 阅片时应重点评估动脉期高强化作为不完全坏死的主要征象。
  • 廓清征象对诊断有额外价值,但单独出现概率低。
  • 消融术后病灶检测不完全坏死的敏感度较低,需结合其他征象谨慎判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To perform a systematic review and meta-analysis using individual patient data to investigate the diagnostic performance of Liver Imaging Reporting and Data System (LI-RADS) Treatment Response (TR) algorithm for detecting incomplete necrosis on pathology.

METHODS: PubMed and EMBASE were searched from Jan 1, 2017 until October 14, 2020. Studies reporting diagnostic accuracy of LI-RADS TR algorithm on CT or MRI for detecting incomplete necrosis on pathology as a reference standard were included. Sensitivity and specificity were pooled using random-effects model. Subgroup analyses were performed for locoregional treatment (LRT) type and imaging modality.

RESULTS: Six studies (393 patients, 534 lesions) were included. Pooled sensitivity was 0.56 (95% confidence interval [CI] 0.43-0.69) and specificity was 0.91 (95%CI 0.84-0.96). Pooled sensitivity was highest using arterial phase hyperenhancement (APHE) (0.67 [95%CI 0.51-0.81]), followed by washout (0.43 [95%CI 0.26-0.62]) and enhancement similar to pretreatment (0.24 [95%CI 0.15-0.36]). Among lesions with incomplete necrosis, 2% (95%CI 0.00-0.05) manifested as washout but no APHE; 0% (95% CI 0.00-0.02) as enhancement similar to pretreatment without both APHE and washout. Pooled sensitivity was lower after ablation than embolization (0.42 [95%CI, 0.28-0.57] vs. 0.65 [95%CI, 0.53-0.77], p = 0.033). MRI and CT were comparable (p = 0.783 and 0.290 for sensitivity and specificity).

CONCLUSIONS: LI-RADS TR algorithm shows moderate sensitivity and high specificity for detecting incomplete necrosis after LRT. APHE is the dominant criterion, a washout contributes to small but meaningful extent, while the contribution of enhancement similar to pretreatment may be negligible. LRT type may affect performance of the algorithm.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Kim TH, Woo S, Joo I, et al. LI-RADS treatment response algorithm for detecting incomplete necrosis in hepatocellular carcinoma after locoregional treatment: a systematic review and meta-analysis using individual patient data. Abdom Radiol (NY). 2021. PMID: 34027566. doi:10.1007/s00261-021-03122-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。